Discussion
toxicity, cancers, ESCC, tumor
METASTASIS, CANCERS, RECURRENCE, TUMOR
In this phase II trial conducted in 47 patients with locally advanced ESCC, the pCR and MPR were 33.3% and 64.3%, respectively, and the ORR was 80.0%. Forty-two patients received surgery, and R0 resection was achieved in 100% of patients having undergone surgery. Three treatment cycles elicited a significantly higher rate of T down-staging than two (84.4% vs. 62.2%) without a significant increase in TRAEs. The most common TRAEs were grade 1–2, and no surgical delay was reported. With a median follow-up of 24.3 months, the 1-year DFS and OS rates were both 97.6%, and the 2-year DFS and OS rates were 92.3% and 97.6%, respectively. The density of CD56Neoadjuvant therapy is recommended in many cancers to achieve tumor downstaging and improve the curative rate. However, different cycles of neoadjuvant treatment could influence the prognosis and the quality of perioperative life. In a randomized phase II study [The toxicity of intensive cycles of camrelizumab plus chemotherapy was tolerated. Most of the TRAEs were grade 1–2, which was similar to previous data of two treatment cycles [For surgery completion, R0 resection was achieved in 100% of patients who underwent surgery, which was consistent with that of other two-cycle regimens (96.3–100%) [In this study, the pCR rate was 33.3%, similar to the results from other immunochemotherapy trials of ESCC. Taking an intensive-cycle regimen does not seem to impact the pCR (data from two-cycle immunochemotherapy studies: 25–35.3%) [Furthermore, our study found that 2.4% (1/42) of patients developed local recurrence and 4.8% (2/42) experienced distant metastasis at a median follow-up time of 24.3 months after surgery, which were numerically lower than the respective rates of 20% (4/20) and 10% (2/20) observed in patients who received two cycles of neoadjuvant PD-1 blockade plus chemotherapy at a median follow-up time of 13.5 months [The pathological response was significantly predictive of prognosis [Molecular genetic analyses demonstrated multiple genetic abnormalities in ESCC. Our study found some specific driver mutations, including To summarize, intensive cycles of neoadjuvant chemotherapy combined with camrelizumab demonstrated favorable efficacy and acceptable toxicity, particularly an encouraging 1-year DFS and OS. The abundance of CD56